keyword
MENU ▼
Read by QxMD icon Read
search

zoledronic

keyword
https://www.readbyqxmd.com/read/29235095/immune-cells-regulate-vegf-signaling-via-release-of-vegf-and-antagonistic-soluble-vegf-receptor-1
#1
Timm Hoeres, Martin Wilhelm, Manfred Smetak, Elisabeth Holzmann, Gundula Schulze-Tanzil, Josef Birkmann
Vascular endothelial growth factor (VEGF) is an important regulator of physiological and pathological angiogenesis. Beside malignant and stromal cells, local immune cells shape VEGF signaling in the tumor microenvironment. Aminobisphosphonates like zoledronic acid (Zol) are drugs known to inhibit osteoclast activity and bone resorption, but also have immunomodulatory and anti-tumor effects. These properties have previously been linked to the downregulation of VEGF and interference with tumor neo-angiogenesis...
December 13, 2017: Clinical and Experimental Immunology
https://www.readbyqxmd.com/read/29234591/reproductive-hormone-analyses-and-effects-of-adjuvant-zoledronic-acid-in-early-breast-cancer-an-azure-big-01-04-sub-study
#2
Caroline Wilson, Samantha Hinsley, Helen Marshall, David Cameron, Richard Bell, David Dodwell, Robert E Coleman
Purpose: Adjuvant bisphosphonates have been shown to improve disease outcomes in early breast cancer in women who are postmenopausal at the start of treatment. We explored the influence of pretreatment serum levels of reproductive hormones in the hypothalamic-pituitary-gonadal (HPG) axis from a subset of patients included in the AZURE trial to investigate their impact on disease recurrence and whether reproductive hormone measurements are of value in selecting patients for treatment with adjuvant zoledronic acid...
November 2017: Journal of Bone Oncology
https://www.readbyqxmd.com/read/29233701/in%C3%A2-vivo-effects-of-geranylgeraniol-on-the-development-of-bisphosphonate-related-osteonecrosis-of-the-jaws
#3
Filip Koneski, Danica Popovic-Monevska, Icko Gjorgoski, Jovanka Krajoska, Mirjana Popovska, Ilijana Muratovska, Boris Velickovski, Gordana Petrushevska, Vladimir Popovski
BACKGROUND: Bisphosphonate-related osteonecrosis of the jaws (BRONJ) is a complication of the bisphosphonate (BP) treatment and its pathopysiology is still not fully understood. The existing preventive and treatment options require updates and more attention. Geranylgeraniol (GGOH) so far demonstrated an increased activity and viability of the cells previously treated with zoledronic acid (ZA). The aim of this study was to evaluate the in vivo effects of GGOH on the development of BRONJ...
November 20, 2017: Journal of Cranio-maxillo-facial Surgery
https://www.readbyqxmd.com/read/29230158/significant-improvement-of-clinical-symptoms-bone-lesions-and-bone-turnover-after-long-term-zoledronic-acid-treatment-in-patients-with-a-severe-form-of-camurati-engelmann-disease
#4
Giampiero I Baroncelli, Elena Ferretti, Cecilia M Pini, Benedetta Toschi, Rita Consolini, Silvano Bertelloni
Camurati-Engelmann disease (CED) is an ultrarare autosomal dominant bone dysplasia. Cortical thickening of the diaphyses of the long bones with narrowing of the medullary cavity are associated with bone pain, waddling gait, muscular weakness, easy fatigability, and a marfanoid body habitus. There is no specific treatment for CED. Nonsteroidal anti-inflammatory drugs or glucocorticoids are ineffective in improving bone lesions. A family with a mild to severe form of CED is described. Two patients received long-term bisphosphonate treatment: the 19-year-old female proband was treated with zoledronic acid for 2...
November 2017: Molecular Syndromology
https://www.readbyqxmd.com/read/29224174/cost-effectiveness-of-treatments-for-the-management-of-bone-metastases-a-systematic-literature-review
#5
REVIEW
Lazaros Andronis, Ilias Goranitis, Sue Bayliss, Rui Duarte
BACKGROUND: Metastatic cancers occur when cancer cells break away from the primary tumour. One of the most common sites of metastasis is the bone, with several therapeutic options currently available for managing bone metastases. In a resource-constrained environment, policy makers and practitioners need to know which options are cost effective. OBJECTIVE: The aim of this systematic review was to review and appraise published economic evaluations on treatments for the management of bone metastases...
December 9, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/29215680/effects-of-zoledronic-acid-in-experimental-periapical-lesions-in-rats-an-imaging-and-histological-analysis
#6
Talita Ribeiro Tenório de França, Flávia Maria de Moraes Ramos-Perez, Andrea Dos Anjos Pontual, Jurema Freire Lisboa de Castro, Paulo Rogério Ferreti Bonan, Danyel Elias da Cruz Perez
The aim of this study was to assess the imaging and histological features of experimental periapical lesions, including the adjacent alveolar bone, in rats under zoledronic acid treatment. The study used 40 male Wistar rats distributed into 8 groups of 5 animals each: G1: induction of periapical lesion (PL) and weekly intraperitoneal administration (WIPA) of saline solution (0.9% NaCl) for 4 weeks; G2: PL induction and WIPA of zoledronic acid (0.15 mg/kg/week) for 4 weeks; G3: PL induction and WIPA of saline solution for 8 weeks; G4: PL induction and WIPA of zoledronic acid for 8 weeks; G5:WIPA of saline solution for 4 weeks and subsequent PL induction; G6: WIPA of zoledronic acid for 4 weeks and subsequent PL induction; G7: WIPA of saline solution for 8 weeks and subsequent PL induction; G8: WIPA of zoledronic acid for 8 weeks and subsequent PL induction...
September 2017: Brazilian Dental Journal
https://www.readbyqxmd.com/read/29204337/effects-on-bone-resorption-markers-of-continuing-pamidronate-or-switching-to-zoledronic-acid-in-patients-with-high-risk-bone-metastases-from-breast-cancer
#7
J F Hilton, M Clemons, G Pond, H Zhao, S Mazzarello, L Vandermeer, C L Addison
Background: Switching patients who remain at high risk of skeletal related events (SREs) despite pamidronate to the more potent bisphosphonate zoledronate, may be an effective treatment strategy. As part of a previously reported clinic study in this setting, we evaluated whether biomarkers for bone resorption, such as Bone-Specific Alkaline Phosphatase (BSAP), bone sialoprotein (BSP), and N-terminal telopeptide (NTX) correlated with subsequent SRE risk. Methods: Breast cancer patients who remained at high risk of SREs despite at least 3 months of q...
March 2018: Journal of Bone Oncology
https://www.readbyqxmd.com/read/29201194/protective-effect-of-zoledronic-acid-on-articular-cartilage-and-subchondral-bone-of-rabbits-with-experimental-knee-osteoarthritis
#8
Guorong She, Ziqi Zhou, Zhengang Zha, Fei Wang, Xiaoting Pan
Subchondral bone reabsorption and remodeling are responsible for the initiation and progression of osteoarthritis (OA). Zoledronic acid (ZOL), a third-generation bisphosphonate (BIS), is an inhibitor of bone reabsorption. However, the intervention effect of ZOL on OA has not been fully characterized and remains to be directly demonstrated in animal experiments. The present study examined the microscopic and macroscopic changes in the anterior cruciate ligament transection (ACLT) model of OA in rabbits and evaluated the effects of ZOL on cartilage degeneration and subchondral bone loss...
November 2017: Experimental and Therapeutic Medicine
https://www.readbyqxmd.com/read/29196083/the-good-and-the-bad-about-the-2017-american-college-of-physicians-osteoporosis-guidelines
#9
Violet Lagari, Tara Gavcovich, Silvina Levis
PURPOSE: The American College of Physicians (ACP) published a set of guidelines on how to prevent fractures in men and women with low bone density or osteoporosis. As the population ages, the overall risk of fractures increases, thus burdening the health care system. These guidelines review current evidence for osteoporosis management, providing an update to the previous 2008 ACP's guidelines. METHODS: The ACP put forth 6 recommendations addressing the complexities in osteoporosis management based on evidence available through October 2016 with a focus on bisphosphonates, calcium, vitamin D, and estrogen...
November 28, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/29194749/longitudinal-effects-of-teriparatide-or-zoledronic-acid-on-bone-modeling-and-remodeling-based-formation-in-the-shotz-study
#10
David W Dempster, Hua Zhou, Valerie A Ruff, Thomas E Melby, Jahangir Alam, Kathleen A Taylor
Previously we reported on bone histomorphometry, biochemical markers, and bone mineral density distribution following 6 and 24 months of treatment with teriparatide (TPTD) or zoledronic acid (ZOL) in the SHOTZ study. The study included a 12-month primary study period, with treatment (TPTD 20 μg/day by subcutaneous injection or ZOL 5 mg/year by intravenous infusion) randomized and double-blind until the month 6 biopsy (TPTD n=28, ZOL n=30 evaluable), then open-label, with an optional 12-month extension receiving the original treatment...
November 30, 2017: Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research
https://www.readbyqxmd.com/read/29192423/bisphosphonates-for-paget-s-disease-of-bone-in-adults
#11
REVIEW
Luis Corral-Gudino, Adrian Jh Tan, Javier Del Pino-Montes, Stuart H Ralston
BACKGROUND: Bisphosphonates are considered to be the treatment of choice for people with Paget's disease of bone. However, the effects of bisphosphonates on patient-centred outcomes have not been extensively studied. There are insufficient data to determine whether reducing and maintaining biochemical markers of bone turnover to within the normal range improves quality of life and reduces the risk of complications. OBJECTIVES: To assess the benefits and harms of bisphosphonates for adult patients with Paget's disease of bone...
December 1, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29192319/zoledronic-acid-dosing-in-patients-with-metastatic-breast-cancer-reply
#12
Gabriel N Hortobagyi, Ming Zheng
No abstract text is available yet for this article.
November 30, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/29192317/zoledronic-acid-dosing-in-patients-with-metastatic-breast-cancer
#13
Charles L Shapiro, Andrew L Himelstein
No abstract text is available yet for this article.
November 30, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/29192309/zoledronic-acid-dosing-in-patients-with-metastatic-breast-cancer
#14
Takahiro Hasegawa, Hajime Uno, Lee-Jen Wei
No abstract text is available yet for this article.
November 30, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/29190507/results-of-methotrexate-etoposide-ifosfamide-based-regimen-m-ei-in-osteosarcoma-patients-included-in-the-french-os2006-sarcome-09-study
#15
Nathalie Gaspar, Bob-Valéry Occean, Hélène Pacquement, Emmanuelle Bompas, Corine Bouvier, Hervé J Brisse, Marie-Pierre Castex, Nadir Cheurfa, Nadège Corradini, Jessy Delaye, Natacha Entz-Werlé, Jean-Claude Gentet, Antoine Italiano, Cyril Lervat, Perrine Marec-Berard, Eric Mascard, Françoise Redini, Laure Saumet, Claudine Schmitt, Marie-Dominique Tabone, Cécile Verite-Goulard, Marie-Cécile Le Deley, Sophie Piperno-Neumann, Laurence Brugieres
BACKGROUND: In most countries, reference chemotherapy for osteosarcoma is MAP regimen (M = high-dose methotrexate, AP = doxorubicin-cisplatinum). In France, the standard preoperative chemotherapy for children/adolescents combines M and etoposide-ifosfamide (EI), based on the OS94-trial. We report the safety and efficacy results of patients ≤25 years treated with preoperative M-EI regimen enroled in the French OS2006-study, between 2007 and 2014. METHODS: Treatment comprised preoperative chemotherapy with the 7 M-courses and 2 EI-courses, then surgery and postoperative chemotherapy assigned by risk's groups: standard-risk (good histological response without metastases) received 12 M-courses, 3 EI-courses; high-risk (poor histologic response, initial metastases or unresectable primary) received 5 M-courses alternated with 5 AP-courses...
November 27, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/29188452/bisphosphonates-hinder-osteoblastic-osteoclastic-differentiation-in-the-maxillary-sinus-mucosa-derived-stem-cells
#16
Jun Zhang, Jaesuh Park, Jung-Woo Lee, Yong-Dae Kwon, Eun-Cheol Kim
OBJECTIVES: Although bisphosphonates (BPs) are known to be associated with osteonecrosis of the maxilla, the precise effects of BPs on bone metabolism in human maxillary sinus mucosal cells (HMSMCs) are not yet known. The purposes of this study were to examine the effects of the BPs zoledronate (ZOL) and alendronate (ALN) on osteoblastic and osteoclastic differentiation in HMSMCs and to investigate the signaling pathways involved. MATERIALS AND METHODS: The effects of ZOL and ALN were assessed for osteoblast differentiation by alkaline phosphatase (ALP) activity, alizarin red staining, and RT-PCR for genes encoding Runx2 and osterix...
November 30, 2017: Clinical Oral Investigations
https://www.readbyqxmd.com/read/29184807/zoledronic-acid-in-pediatric-metabolic-bone-disorders
#17
REVIEW
Sasigarn A Bowden, John D Mahan
Zoledronic acid (ZA), a highly potent intravenous bisphosphonate (BP), has been increasingly used in children with primary and secondary osteoporosis due to its convenience of shorter infusion time and less frequent dosing compared to pamidronate. Many studies have also demonstrated beneficial effects of ZA in other conditions such as hypercalcemia of malignancy, fibrous dysplasia (FD), chemotherapy-related osteonecrosis (ON) and metastatic bone disease. This review summarizes pharmacologic properties, mechanism of action, dosing regimen, and therapeutic outcomes of ZA in a variety of metabolic bone disorders in children...
October 2017: Translational pediatrics
https://www.readbyqxmd.com/read/29180210/survival-outcomes-of-neoadjuvant-chemotherapy-with-zoledronic-acid-for-her2-negative-breast-cancer
#18
Takashi Ishikawa, Kouhei Akazawa, Yoshie Hasegawa, Hirokazu Tanino, Jun Horiguchi, Daishu Miura, Mitsuhiro Hayashi, Norio Kohno
BACKGROUND: A randomized phase 2 trial in women with HER2-negative breast cancer has shown that adding zoledronic acid (ZOL) to neoadjuvant chemotherapy (CT) has potential anticancer benefits in postmenopausal and triple-negative (TN) breast cancer patients. We report the data for the secondary end point of disease-free survival (DFS). METHODS: Patients were randomly assigned to receive CT or CT + ZOL (CT-Z). All patients received four cycles of FEC100 followed by 12 cycles of paclitaxel weekly...
December 2017: Journal of Surgical Research
https://www.readbyqxmd.com/read/29179892/update-on-osteoporosis-treatment
#19
REVIEW
Xavier Nogués, Daniel Martinez-Laguna
Treatment of osteoporosis should be directed primarily towards secondary prevention of fractures. The occurrence of drug-related adverse effects for the treatment of osteoporosis has led to a reevaluation of the indications, the duration of treatment and even withdrawal of some drugs from the market. This review has been made from different patient profiles that practitioners will find in usual practice; from patients with hip fracture with cognitive impairment, limitation of their day-to-day living activities and comorbidities, to active patients without any limitations; patients with vertebral fractures and non-vertebral fractures where secondary prevention is highly important...
November 24, 2017: Medicina Clínica
https://www.readbyqxmd.com/read/29177700/novel-mutations-in-plod2-cause-rare-bruck-syndrome
#20
Fang Lv, Xiaojie Xu, Yuwen Song, Lujiao Li, Asan, Jian Wang, Huanming Yang, Ou Wang, Yan Jiang, Weibo Xia, Xiaoping Xing, Mei Li
Bruck syndrome is a rare autosomal recessive form of osteogenesis imperfecta (OI), which is mainly characterized by joint contractures and recurrent fragility fractures. Mutations in FKBP10 and PLOD2 were identified as the underlying genetic defects of Bruck syndrome. Here we investigated the phenotypes and the pathogenic mutations of three unrelated Chinese patients with Bruck syndrome. Clinical fractures, bone mineral density (BMD), bone turnover biomarkers, and skeletal images were evaluated in detail. The pathogenic mutations were identified by targeted next-generation sequencing and subsequently confirmed by Sanger sequencing and cosegregation analysis...
November 24, 2017: Calcified Tissue International
keyword
keyword
113547
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"